CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash
SAN FRANCISCO, July 29, 2026 (GLOBE NEWSWIRE) -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to submit your losses now.
The national investor rights firm has opened an investigation into whether Capricor misled investors about the efficacy and trial results of its lead product candidate, Deramiocel, intended for the treatment of Duchenne muscular dystrophy (DMD).
Visit: www.hbsslaw.com/investor-fraud/capr
Contact the Firm Now: CAPR@hbsslaw.com
844-916-0895
Capricor Therapeutics (CAPR) Investigation
The investigation focuses on disclosures that emerged on July 27, 2026, when Capricor shares plummeted roughly 40% to 64% following the U.S. Food and Drug Administration's (FDA) publication of its briefing document ahead of the advisory committee meeting for Deramiocel’s biologics license application (BLA).
The sharp drop was triggered by potential discrepancies between how Capricor characterized its Phase 3 HOPE-3 trial results and the FDA's analytical findings regarding the data and trial parameters.
The HOPE-3 Trial Breakthrough and Subsequent Capital Raise
On December 3, 2025 Capricor announced “Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy.”
The company’s CEO said “HOPE-3 delivered strong and definitive evidence that Deramiocel can meaningfully improve the course of Duchenne muscular dystrophy, demonstrating statistically significant improvements in both skeletal and cardiac function.”
In response, the market sent the price of Capricor shares up $23.60, or 370% higher on December 3, 2025. The next day, the company launched a proposed public offering of its shares which included about 6 million shares priced at $25 per share.
FDA Briefing Document Reveals SAP Changes and Triggers 64% Stock Collapse
Capricor’s assurances about its Deramiocel “strong and definitive evidence” came into question on July 27, 2026. That day, the FDA published its briefing report for the July 29, 2026 meeting being held to consider Capricor’s resubmitted BLA for Deramiocel. The brief focused in large part on Capricor’s statistical analysis plan (“SAP”), which governed how clinical trial data is analyzed to determine if a drug has met its predefined efficacy and safety endpoints.
In contrast to Capricor’s December claims, the FDA said in the brief that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.”
The FDA also said, “changes were made to the pre-specified [SAP], generating at least 2 additional versions[,]” and “[t]hose changes included modifications to the primary and key secondary endpoint definitions; the analytical methods; and the data imputation for certain intercurrent events.”
The market quickly digested the news, sending the price of Capricor shares down about 64% to close at $7 on July 27.
“We’re focused on the extent to which Capricor disclosed SAP modifications and their implications for the BLA,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Capricor and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to frequently asked questions about the firm’s Capricor investigation, read more »
Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email CAPR@hbsslaw.com.
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.
Contact:
Reed Kathrein, 844-916-0895
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
